All Clinical Trials
Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.
322 trials found
Drug |
NCT# |
||
|---|---|---|---|
| Avapritinib (CS3007) | A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor | 1/2 |
|
| CB-839 + Talazoparib | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | 1/2 |
|
| CS1001 + Regorafenib | A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors | 1/2 |
|
| DCC-3116 + Ripretinib | A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies | 1/2 |
|
| EDO-S101 | Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors | 1/2 |
|
| Imatinib + BGJ398 | BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | 1/2 |
|
| Imatinib + MEK162 | MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | 1b/2 |
|
| Imatinib + PDR001 | PDR001 Plus Imatinib for Metastatic or Unresectable GIST | 1/2 |
|
| Imatinib + Selinexor | Selinexor in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. (SeliGIST) | 1/2 |
|
| PDR001 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | 1/2 |
|
| Regorafenib + Avelumab | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | 1/2 |
|
| THE-630 | A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | 1/2 |
|
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | 4 |
||
| Imatinib | Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) (Japan CSTI571BJP07) | 4 |
|
| Imatinib + Sunitinib + Regorafenib | Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients | 4 |
|
| Sunitinib | Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutent | 4 |
|
| Sunitinib | Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor (GIST) | 4 |
|
| Sunitinib | Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients | 4 |
|
| Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST) | 3 |
||
| Avapritinib or Regorafenib | (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | 3 |
|
| Bezuclastinib plus Sunitinib | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | 3 |
|
| Crenolanib (CP-868,596) | Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST | 3 |
|
| Famitinib | Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib | 3 |
|
| Imatinib | Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (S0033) | 3 |
|
| Imatinib | Imatinib Mesylate (Gleevec; STI571) in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed by Surgery (ACOSOG-Z9001) | 3 |
|
| Imatinib | Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor (EORTC-62024) | 3 |
|
| Imatinib | Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) (SSGXVIII/AIO) | 3 |
|
| Imatinib | Open-Label Trial of Glivec With Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors | 3 |
|
| Imatinib | Prospective Multicentric Randomized Study of Glivec® in Advanced Gastrointestinal Stromal Tumors Expressing c-Kit: Interruption After 5 Years vs Maintenance | 3 |
|
| Imatinib | Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor (EORTC-62005) | 3 |
|
| Imatinib | Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate | 3 |
|
| Imatinib | Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | 3 |
|
| Imatinib | Rechallenge of Imatinib in GIST Having no Effective Treatment (RIGHT) | 3 |
|
| Imatinib | Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist) | 3 |
|
| Imatinib | Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST | 3 |
|
| Imatinib + Bevacizumab | Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor | 3 |
|
| IPI-504 | Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib | 3 |
|
| L-carnitine | L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors | 3 |
|
| Masitinib or Sunitinib | Masitinib 2nd Line versus Sunitinib in Advanced GIST | 3 |
|
| Masitinib, (AB1010) | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment | 3 |